^
Association details:
| Biomarker: | HR negative |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Regimen: | TCHP (carboplatin + docetaxel + Herceptin (trastuzumab) + Perjeta (pertuzumab)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Real Would Evidence (RWE) of neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in patients with HER2 positive early or locally advanced breast cancer treated Single institutional experience
Published date:
11/17/2020
Excerpt:
...447 patients were treated with neoadjuvant TCHP...Median age at BC diagnosis was 56. In clinical stage, stage II was 54.6% and 45.4% of stage III and hormone receptor (HR) positive BC was 48.3%...pCR rate was 64%; 77% of HR negative BCs and 50% of HR positive BCs…Estimated 3year recurrence free survival of patients with pCR was 95% and 87% of whom without pCR (P=.022)…
